nding its approval for use in certain adult patients with hypercholesterolemia. The European Commission (EC) is expected to make a final decision on the Marketing Authorization Application for Praluent in the European Union in September 2015. Investor Relations Conference Call on Praluent Sanofi and Regeneron will be hosting a conference call for t